Depression Therapy to Improve Cardiovascular Risk in HIV

Depression Clinical Trial

Official title:

A Randomized, Controlled Pilot Trial Assessing the Utility of Cognitive Behavioral Therapy to Improve Endothelial Function and Reduce Inflammation in Depressed, Virologically-Suppressed, Antiretroviral-Treated, HIV-infected Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02309372
• Other study ID #: R01HL126557
• Status: Completed
• Phase: N/A
• Start date: April 2015
• Est. completion date: April 2019

Study information

• Verified date: July 2020
• Source: Indiana University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial will determine if depression treatment will reduce cardiovascular risk in HIV-infected patients already receiving HIV treatments. Half of the participants will undergo a specific computerized depression treatment with the other half receiving usual care from their HIV providers.

Description:

The objectives of this study will be met by performing a 24-week, randomized, controlled, single-blinded, two-arm, parallel group, pilot trial at a single center. A total of 200 subjects may be screened to identify 110 participants to be enrolled and randomized. These participants will be ≥ 18 years old, have been receiving antiretroviral therapy for at least one year with an HIV viral load < 75 copies/mL at screening, and have major depression using the PHQ-9 questionnaire. These participants will be randomized 1:1 to either depression treatment with the Beating-the-Blues cognitive behavioral therapy program (N=55) or usual care (N=55).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: April 2019
• Est. primary completion date: April 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HIV-1 infection, documented by both: (1) any licensed rapid HIV test or HIV enzyme test kit at any time prior to study entry and (2) by at least one detectable HIV-1 antigen or at least one detectable plasma HIV-1 RNA viral load

• Age equal to or greater than 18 years

• Receipt of antiretroviral therapy of any kind for at least 360 days prior to screening

Note: Interruptions in ART of up to 14 days total during the 360 days prior to screening are allowed

• HIV-1 RNA level < 75 copies/mL at screening

NOTE: There are no CD4 cell count eligibility criteria for this trial

• For women who are still of reproductive potential, a negative urine pregnancy test

• Depression as defined by having a score = 10 on the PHQ-9 questionnaire

Exclusion Criteria:

• Inability to complete written, informed consent

• Incarceration at the time of any study visit

• Active suicidality, as determined by the patient's HIV provider or social worker following a positive response (1, 2, or 3) to PHQ-9 Item #9 and a positive response (yes) to one or more of the three questions on the Patient Suicidality Form (with last suicide attempt within the past ten years)

• Diagnosed vascular disease (documented history of angina pectoris, coronary disease, peripheral vascular disease, cerebrovascular disease, aortic aneurysm, or otherwise known atherosclerotic disease)

• History of congestive heart failure, even if currently compensated

• Diagnosed disease or process, besides HIV infection, associated with increased systemic inflammation (including, but not limited to, systemic lupus erythematosis, inflammatory bowel diseases, other collagen vascular diseases)

Note: Hepatitis B or C co-infections are NOT exclusionary

• Known or suspected malignancy requiring systemic treatment within 180 days of screening

NOTE: Localized treatment for skin cancers is not exclusionary

• History of Raynaud's phenomenon

• History of cardiac arrhythmias or cardiomyopathy

• Uncontrolled hyperthyroidism or hypothyroidism, defined as TSH values outside of the local reference range on most recent clinical assessment

• History of carotid bruits

• Systolic blood pressure > 160 mmHg or diastolic blood pressure > 110 mmHg at screening

• Screening estimated glomerular filtration rate (eGFR) < 50 mL/min/1.732 (using the 2009 CKD-EPI equation) using a serum creatinine level measured at screening

• Screening glucose = 140 mg/dL or hemoglobin A1c > 8.0%

• Screening total cholesterol > 240 mg/dL

• Therapy for serious medical illnesses within 14 days prior to screening

Note: Therapy for serious medical illnesses that overlaps with a main study visit will result in postponement of that study visit until the course of therapy is completed; postponement outside of the allowed study visit timeframe will result in study discontinuation

• Pregnancy or breastfeeding during the course of the study

• Receipt of investigational agents, cytotoxic chemotherapy, systemic glucocorticoids (of any dose), or anabolic steroids at screening

Note: Physiologic testosterone replacement therapy or topical steroids is not exclusionary. Inhaled/nasal steroids are not exclusionary as long as the participant is not also receiving HIV protease inhibitors

• Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements

• History of schizophrenia or bipolar disorder

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• HIV

Intervention

Behavioral:
• Beating the Blues
Computerized depression treatment intervention

Locations

Country	Name	City	State
United States	Indiana University Health University Hospital, Indiana Clinical Research Center	Indianapolis	Indiana
United States	Infectious Diseases Research Center	Indianapolis	Indiana

Sponsors (1)

Lead Sponsor	Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Brachial Artery Flow-mediated Dilation From Baseline to Week 12	Changes in flow-mediated dilation of the brachial artery from baseline to week 12. This is calculated by the FMD value at Week 12 minus the FMD value at baseline.	Baseline and Week 12 of participation
Secondary	Changes in Circulating IL-6 From Baseline to Week 12	Interleukin-6 (IL-6) is a measure of systemic inflammation. This is calculated by the IL-6 value at Week 12 minus the IL-6 value at baseline.	Baseline and 12 weeks
Secondary	Change in hsCRP From Baseline to Week 12	hsCRP (high sensitivity C-reactive protein) is a measure of systemic inflammation. This is calculated by the hsCRP value at Week 12 minus the hsCRP value at baseline.	12 weeks
Secondary	Change in D-dimer From Baseline to Week 12	D-dimer is a measure of systemic coagulation. This is calculated by the D-dimer value at Week 12 minus the D-dimer value at baseline.	12 weeks